Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor-lysate loaded dendritic cell vaccine + nivolumab + ipilimumab + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Wuerzburg University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intradermal, Oral, Intravenous
01
Overview
This combination immunotherapy regimen, developed by Wuerzburg University Hospital, is designed for the treatment of relapsed high-grade gliomas in children and adolescents. The protocol involves an individualized cancer vaccine using autologous, tumor-lysate loaded dendritic cells to prime the immune system against tumor antigens. To optimize this response, metronomic cyclophosphamide is administered to deplete immunosuppressive regulatory T cells (Tregs). This is followed by dual checkpoint blockade with nivolumab (targeting PD-1) and ipilimumab (targeting CTLA-4) to prevent T-cell exhaustion and enhance the magnitude and duration of the anti-tumor immune response.
- Other names
- DC Vaccine and Checkpoint Blockade for Relapsed Pediatric High-Grade GliomaDC-Vacc/Nivo/Ipi/Cyc
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on autologous tumor-lysate loaded dendritic cell vaccine + nivolumab + ipilimumab + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor-lysate loaded dendritic cell vaccine + nivolumab + ipilimumab + cyclophosphamide.